Diagnosing irritable bowel syndrome: A changing clinical paradigm

Southern Medical Journal

Volumn 104, Issue 3, 2011, Pages 195-199

  Henderson, Phillip K ^a   DiPalma, Jack A ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

constipation; diarrhea; irritable bowel syndrome

Indexed keywords

ALOSETRON; AMOXICILLIN PLUS CLAVULANIC ACID; BULKING AGENT; DOXYCYCLINE; LINACLOTIDE; LUBIPROSTONE; MACROGOL 3350; MAGNESIUM HYDROXIDE; METRONIDAZOLE; NEOMYCIN; PROBIOTIC AGENT; PRUCALOPRIDE; RIFAXIMIN; RIFAXIMIN PLUS NEOMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; BLOATING; BRISTOL STOOL SCALE; CLINICAL ASSESSMENT; CLINICAL CLASSIFICATION; CLINICAL FEATURE; CONSTIPATION; CONSTIPATION PREDOMINANT INFLAMMATORY BOWEL SYNDROME; DEFECATION HABIT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA PREDOMINANT INFLAMMATORY BOWEL SYNDROME; DIGESTIVE SYSTEM EXAMINATION; DRUG EFFICACY; FAMILY HISTORY; FECES ANALYSIS; HUMAN; IBS JENNIFER; INTERMETHOD COMPARISON; IRRITABLE COLON; KRUIS SCORE; LACTOSE INTOLERANCE; MANNING CRITERIA; MEDICAL HISTORY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; ROME CRITERIA; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT RESPONSE;

HUMANS; IRRITABLE BOWEL SYNDROME; PRACTICE GUIDELINES AS TOPIC;

EID: 79952187413     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31820bfb6c     Document Type: Review

References (35)

1. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S1-S35.
2. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-759. (Pubitemid 38612817)
3. Mayer EA. Irritable bowel syndrome. N Engl J Med 2008;358:1692-1699.
4. Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-1993.
5. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use and costs: a U.S. managed care perspective. Am J Gastroenterol 2003;98:600-607. (Pubitemid 36348532)
6. Thompson WG. Symptoms and syndromes. Am J Gastroenterol 2010; 105:714-717.
7. Spiller R, Camilleri M, Longstreth GF. Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? Clin Gastroenterol Hepatol 2010;8:125-136.
8. Jellema P, Van Der Windt DA, Schellevis FG, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther 2009;30:695-706.
9. Camilleri M. The con argument. Clin Gastroenterol Hepatol 2010;8: 129-131.
10. Longstreth GF. Symptoms and tests for irritable bowel syndrome: diagnosing a complex disorder. Clin Gastroenterol Hepatol 2010;8:132-136.
11. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-654. (Pubitemid 9004104)
12. Kruis W, Thiem C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome: its valuate in the exclusion of organic disease. Gastroenterology 1984;87:1-7. (Pubitemid 14122746)
13. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):II43-II47.
14. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1489-1491.
15. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999;45(suppl II):II1-II5.
16. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.
17. Adeniji OA, Barnett CB, DiPalma JA. Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. Dig Dis Sci 2004; 49:572-574. (Pubitemid 38992543)
18. Owens DM, Nelson DK, Talley NK. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-112.
19. Tolliver BA, Herrera JL, DiPalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994; 89:176-178. (Pubitemid 24054174)
20. Corlew-Roath M, DiPalma JA. Clinical impact of identifying lactose maldigestion or fructose malabsorption in irritable bowel syndrome or other conditions. South Med J 2009;102:1010-1012.
21. Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol 1999;94:1279-1282. (Pubitemid 29214642)
22. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002;97:2812-2819. (Pubitemid 35265433)
23. Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29:834-842.
24. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010;105:848-858.
25. Whitehead WE, Drossman DA. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 2010;105:814-820.
26. Rubin G, De wit N, Meineche-Schmidt V, et al. The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam Pract 2006;23:687-692.
27. Drossman DA. Challenges in the physician-patient relationship: feeling "drained." Gastroenterology 2001;121:1037-1038.
28. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial over-growth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-1286.
29. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145-557-563. (Pubitemid 46780934)
30. Moayyedi P, Forc AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-332.
31. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010;105:866-875.
32. Chatterjee S, Park S, Low K, et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol 2007;102:837-841. (Pubitemid 46496615)
33. Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin in most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010;44: 547-550.
34. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-696. (Pubitemid 351406304)
35. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010;138:813-817.